Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Open Label ◽

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

British Journal of Dermatology ◽

10.1111/bjd.19460 ◽

2020 ◽

Cited By ~ 1

Author(s):

M.J. Cork ◽

D. Thaçi ◽

L.F. Eichenfield ◽

P.D. Arkwright ◽

X. Sun ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Iii ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Open Label Phase ◽

Subsequent Phase

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

10.1016/j.jaad.2019.07.074 ◽

2020 ◽

Vol 82 (2) ◽

pp. 377-388 ◽

Cited By ~ 31

Author(s):

Mette Deleuran ◽

Diamant Thaçi ◽

Lisa A. Beck ◽

Marjolein de Bruin-Weller ◽

Andrew Blauvelt ◽

...

Keyword(s):

Atopic Dermatitis ◽

Extension Study ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Open Label Extension

Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.104 ◽

2020 ◽

Vol 4 (6) ◽

pp. s104

Author(s):

Michael Cork ◽

Diamant Thaçi ◽

Lawrence Eichenfield ◽

Peter Arkwright ◽

Zhen Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Abstract not available.

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct03989206 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

10.1016/j.jaad.2021.06.586 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB143

Author(s):

Andrew Blauvelt ◽

Andreas Wollenberg ◽

Lawrence Eichenfield ◽

Zhen Chen ◽

Debra Sierka ◽

...

Keyword(s):

Atopic Dermatitis ◽

Open Label ◽

Open Label Extension ◽

Term Data

An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04250350 ◽

2020 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Open Label ◽

Safety And Efficacy ◽

Adolescent Patients

Treatment of Severe Atopic Dermatitis Patients with Cyclosporin A(CyA): the Long-Term Safety and Efficacy.

Nishi Nihon Hifuka ◽

10.2336/nishinihonhifu.61.271 ◽

1999 ◽

Vol 61 (3) ◽

pp. 271-278

Author(s):

Yumiko KUBOTA ◽

Shuhei IMAYAMA ◽

Hiroko MIYAHARA ◽

Tomoko TANAHASHI ◽

Yoko UEMURA ◽

...

Keyword(s):

Atopic Dermatitis ◽

Cyclosporin A ◽

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Cited By ~ 19

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

10.1016/j.jaad.2021.06.584 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB142

Author(s):

Andrew Blauvelt ◽

Andreas Wollenberg ◽

Lisa A. Beck ◽

Zhen Chen ◽

Meng Zhang ◽

...

Keyword(s):

Atopic Dermatitis ◽

Laboratory Safety ◽

Open Label ◽

Open Label Extension